Home/Pipeline/Q134R

Q134R

Alzheimer's Disease

Clinical (Partnered)Active

Key Facts

Indication

Alzheimer's Disease

Phase

Clinical (Partnered)

Status

Active

Company

Avidin

About Avidin

Avidin is a diversified biotech firm with a dual focus on therapeutic discovery and molecular diagnostics. Its most advanced program is Q134R, a clinical candidate for Alzheimer's disease developed in partnership with Aperus Pharma. The company also maintains active research in oncology and inflammation, and provides preclinical services and diagnostic products, supported by international scientific and industrial collaborations.

View full company profile

Therapeutic Areas

Oncology Neurodegenerative Diseases Infectious Diseases Inflammation

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active